Skip to main content Back to Top


Penicillin G Benzathine

Reason for the Shortage

    • Pfizer states the shortage was due to a delay in the manufacturing process.

Available Products

    • Bicillin L-A intramuscular suspension for injection, Pfizer, 1,200,000 units, 2 mL syringe, 10 count, NDC 60793-0701-10
    • Bicillin L-A intramuscular suspension for injection, Pfizer, 2,400,000 units, 4 mL syringe, 10 count, NDC 60793-0702-10
    • Bicillin L-A intramuscular suspension for injection, Pfizer, 600,000 units, 1 mL syringe, 10 count, NDC 60793-0700-10

Estimated Resupply Dates

    • Pfizer has Bicillin L-A 600,000 unit/ 1 mL syringes, 1,200,000 unit/ 2 mL syringes, and 2,400,000 unit/ 4 mL syringes available.

Implications for Patient Care

    • Bicillin L-A is the first line treatment of patients with syphilis. CDC is recommending conserving Bicillin L-A for patients with syphilis especially pregnant patients where the treatment choices are more limited. This recommendation can be found at More information regarding treatment of syphilis including alternatives to Bicillin L-A can be found at:


Updated December 18, 2017 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 30, 2016 by Leslie Jensen, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins